C-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 380-392

  Stabile, Laura P ^a   He, Guoqing ^c   Lui, Vivian Wai Yan ^b   Henry, Cassandra ^a   Gubish, Christopher T ^a   Joyce, Sonali ^b   Quesnelle, Kelly M ^b   Siegfried, Jill M ^a   Grandis, Jennifer R ^a,b  

^a University of Pittsburgh School of Medicine   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DASATINIB; ERLOTINIB; KI 67 ANTIGEN; PROTEIN C SRC; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN SYNTHESIS; PROTEIN EXPRESSION;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINAZOLINES; TRANSCRIPTIONAL ACTIVATION;

EID: 84872562509     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1555     Document Type: Article

References (32)

1. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90: 824-32.
2. Kalyankrishna S, Crandis Jr. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24: 2666-72.
3. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22: 77-85.
4. Paez JG, Jänne PA, Lee JC, Tracy S, Greulick H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-500.
5. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318: 287-90.
6. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19: 5636-42.
7. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003;39: 1447-55.
8. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin downregulation, vimentin expression, and aggressive tumor features. Cancer 2008;112: 2088-100.
9. Zhang Q,Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64: 6166-73.
10. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009;15: 3740-50.
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316: 1039-43.
12. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011;17: 4425-38.
13. Zou HY, Li Q, Lee JH, Arango ME, Burgess K, Qiu M, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c- Met kinase inhibitor. Mol Cancer Ther 2012;11: 1036-47.
14. Sacks PG. Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev 1996;15: 27-51.
15. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011;17: 7248-64.
16. Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, et al. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 2007;71: 1435-43.
17. Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008;14: 4284-91.
18. Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither- Davis AL, et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 2008;7: 1913-22
19. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Srcmediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274: 8335-43.
20. Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res 2011;17: 514-24.
21. Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS, et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2011;117: 2112-9.
22. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized Phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small cell lung cancer. J Clin Oncol 2011;29: 3307-15.
23. Niswander LM, Guenther LM, Mendoza A, Khanna C, Christensen JG, Helman LJ, et al. Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo. J Clin Oncol 2010;28:9567.
24. Quesnelle K, Wheeler SM, Ratay M, Grandis Jr. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther 2012;13: 935-945.
25. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333: 1157-60.
26. Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003;278: 31574-83.
27. Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin activates a Shp2- Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol 2006;175: 993-1003.
28. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65: 9185-9.
29. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGFindependent potentiation of EGFR action by c-Met. Oncogene 2011; 30: 3625-35.
30. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, et al. Ligand-independent activation of c-Met by fibronectin and a(5)b(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011;30: 1566-76.
31. Jedlinski A, Ansell A, Johansson AC, Roberg K.EGFRstatus andEGFR ligand expression influence the treatment response of head and neck cancer cell lines. J Oral Pathol Med. 2012 May 29. [Epub ahead of print]
32. Oshima G, Wennerberg J, Yamatodani T, Kjellen E, Mineta H, et al. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2012;138: 491-499.